Medically reviewed by Brigid Dwyer, MD Key Takeaways Disease-modifying therapies slow down the progression of multiple sclerosis. Beta interferon drugs reduce MS attacks by altering the immune ...

Specialists in neuroimaging at UB have proposed a mechanism by which interferon beta-1a may limit brain atrophy in multiple sclerosis (MS) patients. The positive effect of interferon beta-1a, a ...

Patients with clinically isolated syndromes (CIS) are prone to develop multiple sclerosis (MS). The randomized, placebo-controlled CHAMPS trial found early treatment with interferon -1a to be ...

October 24, 2011 (Amsterdam, the Netherlands) — The full results of a phase 3 trial directly comparing alemtuzumab (Lemtrada, Genzyme) with interferon-beta-1a (Rebif, EMD Serono/Pfizer) show a ...

Gilenya and Tascenso ODT are approved to treat relapsing forms of multiple sclerosis (MS) in adults. Gilenya and Tascenso ODT ...

Interferon-beta is a drug approved for the treatment of secondary progressive multiple sclerosis (MS), a relapsing form of the inflammatory autoimmune disease where the body’s own immune system ...

Please provide your email address to receive an email when new articles are posted on . Researchers compared data from those treated in the phase 3 EVOLVE-MS-1 and DECIDE studies. Treatment with ...

NEW YORK (Reuters Health) - Early treatment of multiple sclerosis (MS) patients with interferon beta-1b therapy may help slow down the onset of disability, according to a report in this week's issue ...